Pacira BioSciences acquired by Viatris for $1.7 billion, stock at all-time high
FROM THE WIRE · FINANCE.YAHOO.COM
Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications. Continue Reading
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullish$1.7 billion acquisition of Pacira by Viatris is a significant M&A event for pharma sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Viatris has agreed to acquire Pacira BioSciences for $1.7 billion.
- 02The acquisition includes Pacira's portfolio of non-opioid pain medications.
- 03Pacira stock is having its best day ever following the announcement.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Pacira BioSciences, Inc.36.34 USD+0.08%today +44.19%Positive Viatris Inc.17.39 USD+0.55%today -0.54%Neutral Eli Lilly and Company1,160.44 USD+0.36%today -2.38%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets